A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT00424775
Phase
PHASE1
Status
Terminated

Conditions

  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MK0683, vorinostat — DRUG
    vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.

Study Details

The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.

Key Dates

First listed
Jan 22, 2007
Start date
Jan 31, 2007
Status verified
Mar 2015
Primary completion
Mar 31, 2007
Completion
Mar 31, 2007

Study Design

Enrollment
3 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Number of Participants With a Dose Limited Toxicity at First Cycle [ Time Frame: 25 Days (first cycle) ]

Related Studies